Prospects of medium specific activity <sup>177</sup>Lu in targeted therapy of prostate cancer using <sup>177</sup>Lu‐labeled PSMA inhibitor
Sudipta Chakraborty, Ashutosh Dash(Bhabha Atomic Research Centre), Rubel Chakravarty(Bhabha Atomic Research Centre), Ishita Sen(Fortis Memorial Research Institute), Priyalata Shetty(Bhabha Atomic Research Centre), K.V. Vimalnath(Bhabha Atomic Research Centre)
Cited by 27
Related Papers
Production of 177Lu for Targeted Radionuclide Therapy: Available Options
|Nuclear Medicine and Molecular Imaging|2015|375
Sustained Availability of <sup>99m</sup>Tc: Possible Paths Forward
|Journal of Nuclear Medicine|2012|140
Peptide Receptor Radionuclide Therapy: An Overview
|Cancer Biotherapy and Radiopharmaceuticals|2015|122
Targeted Radionuclide Therapy - An Overview
|Current Radiopharmaceuticals|2013|117
Development of an electrochemical 90Sr–90Y generator for separation of 90Y suitable for targeted therapy
|Nuclear Medicine and Biology|2008|99